news

CUPERTINO, Calif., Jan 14, 2002 (BUSINESS WIRE) — In conjunction with DURECT Corporation’s (NASDAQ:DRRX) fourth quarter and year end 2001 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, January 30, 2002 at 4:30 p.m. EDT with Jim Brown, President and […]

CUPERTINO, Calif., Jan 4, 2002 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 20th Annual Healthcare Conference. The conference is taking place January 7-10th at The Westin St. Francis Hotel in San Francisco. James E. Brown, DVM, Chief Executive Officer will be presenting at the

CUPERTINO, Calif., Nov 16, 2001 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that ALZA Corporation has exercised its option to allow ALZA and Janssen Pharmaceutica Products, L.P., the right to begin negotiations for exclusive sales and marketing rights to DURECT’s lead pain management product, Chronogesic(TM) for the U.S. and Canada. Chronogesic(TM) is

CUPERTINO, Calif., Nov. 1 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Twelfth Annual Health Care Conference. The conference is taking place November 5-7 at The Plaza in New York City. Thomas A. Schreck, Chief Financial Officer will be presenting at the conference on Monday, November

CUPERTINO, Calif., Nov. 1 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced during its third quarter financial results conference call yesterday that the company has commenced its Phase III program for Chronogesic(TM), for the treatment of chronic pain. The primary objectives of the Phase III program are to continue to demonstrate that the product is safe,

CUPERTINO, Calif., Oct. 31 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2001. The company’s net loss attributable to common stockholders for the three months ended September 30, 2001 was $8.9 million or 19 cents per share compared to $6.0 million, or 62 cents per share,

CUPERTINO, Calif., Oct 25, 2001 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced yesterday research results showing in animal models that new blood vessels are formed and that blood flow to an ischemic heart can be restored following targeted delivery of fibroblast growth factor to the heart. Dr. Randolph M. Johnson, DURECT’s Vice President

CUPERTINO, Calif., Oct 16, 2001 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present on technologies for targeted drug delivery at the Techvest 3rd Annual Conference on Tissue Repair, Replacement and Regeneration (TR3). The conference is scheduled for October 23rd and 24th at the Hilton New York. Randolph M. Johnson,

CUPERTINO, Calif., Oct 15, 2001 /PRNewswire via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, October 31, 2001 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive

CUPERTINO, Calif., Sept. 24 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Judy Magruder has been promoted to the position of Senior Vice President of Regulatory and Development and Tai Wah Chan, Ph.D. has been promoted to Vice President of Pharmaceutical Research and Development effective September 1, 2001. “We are pleased to announce the